Selective serotonin reuptake inhibitors and tricyclic antidepressants differentially affect heart failure risk in patients with kidney failure
Selektive Serotonin-Wiederaufnahmehemmer und trizyklische Antidepressiva beeinflussen das Herzinsuffizienzrisiko bei Patient:innen mit Nierenversagen unterschiedlich
Clinical Kidney Journal · 01.10.2026 · 19 (10)
DOI: 10.1093/ckj/sfag255 ↗Auf einen Blick
Bei 3.096 Patient:innen mit Nierenversagen und Depression war unter trizyklischen Antidepressiva das Risiko für neu auftretende Herzinsuffizienz höher als unter SSRI. Die Gesamtmortalität unterschied sich nicht.
Fragestellung
Unterscheidet sich das kardiovaskuläre Risiko bei Patient:innen mit Nierenversagen und Depression zwischen SSRI und trizyklischen Antidepressiva?
Methode
Daten aus der Korean National Health Institute Database System; Vergleich von Patient:innen mit Depression nach KF-Diagnose zwischen 2003 und 2022; 1:1-Propensity-Score-Matching und multivariate Analysen.
Ergebnisse
3096 Patient:innen: 2169 mit TCA, 927 mit SSRI. Nach Matching je 844 Patient:innen. Herzinsuffizienz: HR 1,21 (95 %-KI 1,07–1,36) für TCA vs. SSRI; keine signifikanten Unterschiede bei der Gesamtmortalität.
Schlussfolgerung der Autor:innen
Bei Patient:innen mit Depression nach KF-Diagnose war SSRI mit einem niedrigeren Risiko für neu auftretende Herzinsuffizienz verbunden als TCA. Individuelle Antidepressiva-Strategien sollten erwogen werden.
Kernaussagen
- TCA waren mit höherem Risiko für neu auftretende Herzinsuffizienz verbunden
- HR 1,21 (95 %-KI 1,07–1,36) für TCA vs. SSRI
- Keine signifikanten Unterschiede in der Gesamtmortalität
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.08.2026. Verfasst von Yun Seob Jung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Yonsei University Wonju College of Medicine, Wonju, Korea. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Technology R&D Project, Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Although selective serotonin reuptake inhibitors (SSRIs) are the treatment of choice for dialysis patients, tricyclic antidepressants (TCAs) are still frequently prescribed in clinical practice. No studies have compared the cardiovascular outcomes of patients with kidney failure (KF) and depression prescribed SSRIs and those of patients with KF and depression prescribed TCAs.
Methods
Data of patients who were diagnosed with depression after being diagnosed with KF between January 2003 and December 2022 were extracted from the Korean National Health Institute Database System. The primary outcome was incident heart failure. Secondary outcomes included all-cause mortality and other cardiovascular outcomes.
Results
We extracted the data of 3096 patients who were prescribed a single type of antidepressant that was continued throughout the follow-up period. Among these patients, 2169 were prescribed TCAs (mean age, 59.3 years; 57.4% were male), and 927 were prescribed SSRIs (mean age, 60.5 years; 48.8% were male) after KF was diagnosed. After 1:1 propensity score matching, 844 patients remained in each group, and no significant difference in all-cause mortality was observed between patients prescribed TCAs and those prescribed SSRIs. However, the risk of incident heart failure associated with TCA use was higher than that associated with SSRI use [adjusted hazard ratio (HR) 1.21, 95% confidence interval (CI) 1.07–1.36]. This result was consistent with those indicated by the unmatched multivariate adjusted analysis and landmark analysis.
Conclusions
Among patients who were diagnosed with depression after being diagnosed with KF, SSRI use was associated with a lower risk of incident heart failure than TCA use. Individualized antidepressant treatment strategies should be considered for patients at high risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Department of Data Science, Hanmi Pharm. Co., Ltd, Seoul, Korea.
- Department of Family Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Department of Precision Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
- Yonsei University Wonju Health System, Wonju, Korea.
ORCID-Profile: Byoung Geun Han, Jun Young Lee
Förderung
- Korea Health Technology R&D Project
- Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea
- National Research Foundation of Korea
- Medical Research Center Program
- Basic Science Research Program
- Ministry of Education
- Ministry of Science and ICT
Zitieren
APA
Jung, Y. S., Han, B. G., Bae, Y., Shin, D. H., Lee, T. S., Hwang, S. W., Hwang, S., Cha, S. K., Lee, J. Y., & Lee, J. (2026). Selective serotonin reuptake inhibitors and tricyclic antidepressants differentially affect heart failure risk in patients with kidney failure. Clinical Kidney Journal, 19(10). https://doi.org/10.1093/ckj/sfag255
Vancouver
Jung YS, Han BG, Bae Y, Shin DH, Lee TS, Hwang SW, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants differentially affect heart failure risk in patients with kidney failure. Clinical Kidney Journal. 2026;19(10). doi:10.1093/ckj/sfag255
BibTeX
@article{Jung2026,
author = {Jung, Yun Seob and Han, Byoung Geun and Bae, Yoonjong and Shin, Dong Hui and Lee, Tae Sic and Hwang, Sang Won and Hwang, Semi and Cha, Seung-Kuy and Lee, Jun Young and Lee, Jinhee},
title = {Selective serotonin reuptake inhibitors and tricyclic antidepressants differentially affect heart failure risk in patients with kidney failure},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {10},
doi = {10.1093/ckj/sfag255}
}
EUVIMED